Skip to main content
    I

    Ionis Pharmaceuticals Inc (IONS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $26.96
    -1.05 (-3.75%)

    Market Cap: $4.84B

    Last updated: Nov 17, 2026 at 4:38 PM ET

    Ionis Pharmaceuticals Inc (IONS) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Ionis Pharmaceuticals (IONS) has a market cap of $4.84B and an enterprise value of $6.13B. It kept -56.93% of revenue as net income over the last 12 months. Its share count is up 4.03% from a year earlier.

    Total Valuation

    Enterprise value is 26.66% above the market cap, as debt exceeds cash.

    Market Cap$4.84B
    Enterprise Value$6.13B
    Latest price (Nov 17, 2026)$26.96

    Key Dates

    The next earnings report is expected on Feb 23, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 23, 2027 (expected)
    Last Earnings DateNov 9, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 0.48% in the quarter ended Sep 30, 2026 and grew 5.76% a year over 2 years.

    Shares Outstanding166.21M
    Shares Change (YoY)+4.03%
    Shares Change (QoQ)+0.48%
    Share Count Growth (2Y CAGR)+5.76%

    Valuation Ratios

    Sales and book value multiples are 4.7x and 11.4x. Its year-end P/S ranged from 5.7x to 15.7x from 2016 to 2025.

    P/S Ratio4.7x
    Forward P/S5.3x
    P/B Ratio11.4x

    Valuation history and multiples

    Price Statistics

    The stock is down 62.32% over 52 weeks and trades 36.50% below its 50-day average.

    Beta (1Y)0.34
    52-Week Change-62.32%
    1-Month Change-39.25%
    3-Month Change-55.66%
    6-Month Change-63.49%
    5-Year Change+36.55%
    10-Year Change+67.51%
    Total Return (1Y)-62.32%
    Total Return (3Y CAGR)-18.04%
    Total Return (5Y CAGR)-3.46%
    Return vs SPY (1Y)-75.37%
    Max Drawdown (1Y)-68.83%
    Max Drawdown (3Y)-68.83%
    Sharpe Ratio (1Y)-1.97
    Correlation with SPY (1Y)0.09
    50-Day Average$42.46
    200-Day Average$63.94
    52-Week Range$27.25 to $86.74
    RSI (14 Days)21.7
    Average Volume (20 Days)4.79M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 5.43x current liabilities, and total debt is 4.03x shareholder equity.

    Current Ratio5.43x
    Quick Ratio5.36x
    Debt / Equity4.03x
    Interest Coverage-7.63x

    Returns and Efficiency

    Return on invested capital is -29.31% over the last 12 months, against a 5-year average of -19.27%.

    Return on Equity (ROE)-138.84%
    Return on Assets (ROA)-18.76%
    Return on Invested Capital (ROIC)-29.31%
    ROE (5Y Average)-60.13%
    ROA (5Y Average)-9.98%
    ROIC (5Y Average)-19.27%
    Asset Turnover0.32x
    Inventory Turnover0.43x
    Receivables Turnover13.05x
    Cash Conversion Cycle77 days

    Scores

    IONS has an Altman Z-Score of 0.12, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score0.12
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $960.09M over the last 12 months is down 0.71% from the 12 months before.

    Revenue$960.09M
    Revenue Growth (YoY)-0.71%
    Gross Profit$943.09M
    Operating Income-$564.88M
    Pretax Income-$543.72M
    Net Income-$546.54M
    Reported EPS (TTM)-$2.81

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 13.53% of the $2.91B in total assets.

    Cash and Equivalents$296.30M
    Total Debt$1.59B
    Net Debt$1.29B
    Net Debt Per Share$7.76
    Working Capital$1.93B
    Shareholder Equity$393.64M
    Book Value Per Share$2.37
    Total Assets$2.91B
    Total Liabilities$2.52B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $71.85M of capital spending, operating cash flow left -$616.26M of free cash flow.

    Operating Cash Flow-$544.41M
    Capital Expenditures$71.85M
    Free Cash Flow-$616.26M
    FCF Per Share-$3.71
    Depreciation and Amortization$20.03M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -58.84%, against a 5-year average of -45.26%.

    Gross Margin98.23%
    Operating Margin-58.84%
    Pretax Margin-56.63%
    Net Margin-56.93%
    FCF Margin-64.19%
    Gross Margin (5Y Average)98.36%
    Operating Margin (5Y Average)-45.26%
    Net Margin (5Y Average)-40.15%

    Growth

    Revenue grew 17.12% a year over 3 years.

    Revenue Growth (3Y CAGR)+17.12%
    Revenue Growth (5Y CAGR)+5.29%
    Book Value Per Share Growth (2Y CAGR)+6.60%
    Tangible Book Per Share Growth (2Y CAGR)+6.60%

    Revenue and profit by year

    Dividends and Yields

    IONS does not pay a dividend. Its free cash flow yield is -13.75%.

    FCF Yield-13.75%
    Buyback Yield-4.71%
    Shareholder Yield-4.71%

    Peer Position

    Against 6 similar companies, IONS has the 6th highest P/S and the 3rd highest ROIC.

    P/S Ratio4.7x vs 16.1x median
    ROIC-29.31% vs -52.22% median
    Revenue Growth (Trailing 4 Quarters, YoY)-0.71% vs +1.03% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 12.53% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+12.53%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About IONS

    What is IONS's market cap?

    Ionis Pharmaceuticals has a market cap of $4.84B. Its enterprise value, which adds debt and subtracts cash, is $6.13B.

    How many shares of IONS are outstanding?

    Ionis Pharmaceuticals has 166.21M shares outstanding. The count is up 4.03% from a year earlier.

    Does IONS pay a dividend?

    No. Ionis Pharmaceuticals does not pay a dividend.

    How much debt does IONS have?

    Ionis Pharmaceuticals has $1.59B of total debt and $296.30M of cash and equivalents, a net debt position of $1.29B.